Skip to main content

Advertisement

SpringerLink
Log in

The minimal dose of FK506 is sufficient to facilitate the arterialisation of venous allografts in rats

  • Original Article
  • Published:
European Surgery Aims and scope Submit manuscript

Summary

Background

We investigated whether a minimal dose of FK506 is sufficient to inhibit the rejection of venous allografts and facilitate allograft adaptation to arterialisation in rats.

Methods

Iliolumbar veins from Brown Norway (BN) rats were transplanted into the abdominal aorta of Lewis (LEW) rats. Recipient animals received daily intramuscular injections of 0.1 mg kg− 1 FK506. Light microscope evaluations of grafts were performed 30 days after transplantation. We investigated the presence of endothelial cells, the intensity of intimal proliferation, the deposition of immunoglobulin G molecules into the medial layer and the degree of adventitial infiltration by Lewis MHC class II-positive, CD4-positive and CD8-positive cells. All results were compared to previously reported data for syngeneic, allogeneic non-immunosuppressed and allogeneic FK506-low-dose immunosuppressed animals.

Results

All alloveins under minimal FK506 immunosuppression showed typical histological signs of arterialisation 30 days after transplantation. Intimal thickness (15.1 ± 6.1 mm) and the degree of adventitial infiltration by MHC class II-positive (16.96 ± 10.46), CD8-positive (2.63 ± 2.6), and CD4-positive (7.67 ± 8.29) cells were not significantly different when compared to untreated syngeneic veins and allogeneic veins treated with a low dose of FK506, respectively.

Conclusions

Even the minimal dose of FK506 was sufficient to inhibit the acute rejection of venous allografts and to facilitate allograft arterialisation 30 days after transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg. 2000;19 Suppl A:Si-xxviii, S1–250.

    Google Scholar 

  2. Randon C, Jacobs B, De Ryck F, Beele H, Vermassen F. Fifteen years of infrapopliteal arterial reconstructions with cryopreserved venous allografts for limb salvage. J Vasc Surg. 2010;51(4):869–77.

    Article  PubMed  Google Scholar 

  3. Matia I, Janousek L, Marada T, Adamec M. Cold-stored venous allografts in the treatment of critical limb ischaemia. Eur J Vasc Endovasc Surg. 2007;34(4):424–31.

    Article  PubMed  CAS  Google Scholar 

  4. Brockbank KG, McNally RT, Walsh KA. Cryopreserved vein transplantation. J Card Surg. 1992;7(2):170–6.

    Article  PubMed  CAS  Google Scholar 

  5. Posner MP, Makhoul RG, Altman M, Kimball P, Cohen N, Sobel M, et al. Early results of infrageniculate arterial reconstruction using cryopreserved homograft saphenous conduit (CADVEIN) and combination low-dose systemic immunosuppression. J Am Coll Surg. 1996;183(3):208–16.

    PubMed  CAS  Google Scholar 

  6. Matia I, Lodererova A, Adamec M. Delayed administration of FK 506 is sufficient to suppress acute rejection changes after aortal transplantation in rats. Transpl Int. 2007;20(4):371–80.

    Article  PubMed  CAS  Google Scholar 

  7. Matia I, Varga M, Lodererova A, Adamec M. The positive effect of immunosuppression on adaptation of venous allografts to arterialisation in rats. Eur J Vasc Endovasc Surg. 2010;39(4):478–84.

    Article  PubMed  CAS  Google Scholar 

  8. Azuma N, Sasajima T, Kubo Y. Immunosuppression with FK506 in rat arterial allografts: fate of allogeneic endothelial cells. J Vasc Surg. 1999;29(4):694–702.

    Article  PubMed  CAS  Google Scholar 

  9. Kwei S, Stavrakis G, Takahas M, Taylor G, Folkman MJ, Gimbrone MA Jr, et al. Early adaptive responses of the vascular wall during venous arterialization in mice. Am J Pathol. 2004;164(1):81–9.

    Article  PubMed  Google Scholar 

  10. Westerband A, Crouse D, Richter LC, Aguirre ML, Wixon CC, James DC, et al. Vein adaptation to arterialization in an experimental model. J Vasc Surg. 2001;33(3):561–9.

    Article  PubMed  CAS  Google Scholar 

  11. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330(20):1431–8.

    Article  PubMed  CAS  Google Scholar 

  12. Axthelm SC, Porter JM, Strickland S, Baur GM. Antigenicity of venous allografts. Ann Surg. 1979;189(3):290–3.

    Article  PubMed  CAS  Google Scholar 

  13. Wagner E, Roy R, Marois Y, Douville Y, Guidoin R. Posttransplant antibodies and fresh venous allograft failure in dogs. Transplantation. 1994;58(5):537–42.

    Article  PubMed  CAS  Google Scholar 

  14. Stevens SL, Tyler JD, Freeman MB, Hopkins F, Lewis T, Bray J, et al. Factors affecting patency of venous allografts in miniature swine. J Vasc Surg. 1990;12(3):361–6.

    PubMed  CAS  Google Scholar 

  15. Wagner E, Roy R, Marois Y, Douville Y, Guidoin R. Fresh venous allografts in peripheral arterial reconstruction in dogs. Effects of histocompatibility and of short-term immunosuppression with cyclosporine A and mycophenolate mofetil. J Thorac Cardiovasc Surg. 1995;110(6):1732–44.

    Article  PubMed  CAS  Google Scholar 

  16. Carpenter EW, Lindenauer SM. Immunosuppression in arterial and venous allografts. Arch Surg. 1973;106(1):77–8.

    Article  PubMed  CAS  Google Scholar 

  17. Mingoli A, Edwards JD, Feldhaus RJ, Hunter WJ 3rd, Naspetti R, Cavallari N, et al. Fresh vein allograft survival in dogs after cyclosporine treatment. J Surg Res. 1996;62(1):95–102.

    Article  PubMed  CAS  Google Scholar 

  18. Perloff LJ, Reckard CR, Rowlands DT Jr, Barker CF. The venous homograft: an immunological question. Surgery. 1972;72(6):961–70.

    PubMed  CAS  Google Scholar 

  19. Vermassen F, Degrieck N, De Kock L, Goubeau J, Van Landuyt K, Noens L, et al. Immunosuppressive treatment of venous allografts. Eur J Vasc Surg. 1991;5(6):669–75.

    Article  PubMed  CAS  Google Scholar 

  20. Ricotta JJ, Collins GJ Jr, Rich NM, Reynolds DG. Failure of immunosuppression to prolong venous allograft survival. Arch Surg. 1980;115(1):99–101.

    Article  PubMed  CAS  Google Scholar 

  21. Bandlien KO, Toledo-Pereyra LH, MacKenzie GH, Choudhury SP, Cortez JA. Immunosuppression with cyclosporine. A new approach to improve patency of venous allografts. Arch Surg. 1983;118(7):829–33.

    Article  PubMed  CAS  Google Scholar 

  22. Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest. 1986;55(4):455–62.

    PubMed  CAS  Google Scholar 

  23. Khanna A, Kapur S, Sharma V, Li B, Suthanthiran M. In vivo hyperexpression of transforming growth factor-beta1 in mice: stimulation by cyclosporine. Transplantation. 1997;63(7):1037–9.

    Article  PubMed  CAS  Google Scholar 

  24. Miller VM, Bergman RT, Gloviczki P, Brockbank KG. Cryopreserved venous allografts: effects of immunosuppression and antiplatelet therapy on patency and function. J Vasc Surg. 1993;18(2):216–26.

    Article  PubMed  CAS  Google Scholar 

  25. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73(5):775–82.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that there is no actual or potential conflicts of interest in relation to this article.

Author information

Authors and Affiliations

  1. Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21, Prague, Czech Republic

    M. Varga MD & M. Adamec

  2. Department for Visceral, Transplantation, Thoracic and Vascular Surgery, University Hospital Leipzig, Leipzig, Germany

    I. Matia

  3. Department of Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

    A. Lodererova

Authors
  1. M. Varga MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Matia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Lodererova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Adamec
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Varga MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Varga, M., Matia, I., Lodererova, A. et al. The minimal dose of FK506 is sufficient to facilitate the arterialisation of venous allografts in rats. Eur Surg 45, 8–14 (2013). https://doi.org/10.1007/s10353-012-0179-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10353-012-0179-3

Keywords

Search

Navigation